Another downside is that relying too heavily on shakes can cause you to miss out on the variety of nutrients found in whole foods
Overall, Nrf2-targeted therapies remain at an experimental stage, necessitating further drug development for clinical use
these include gastrointestinal adverse events (GI AEs), potential risks of undernutrition, loss of lean body mass, and the propensity for weight regain after treatment cessation [[6], [7], [8], [9]]
While the primary endpoint (cerebral glucose metabolism) was not met, these findings suggest injectable GLP-1s may be more effective than oral formulations
Both are also indicated for the protection of the heart in patients who have excess weight or type 2 diabetes, respectively